TY - BOOK ID - 145198909 TI - Novel Treatment Strategies for Glioblastoma PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - glioblastoma KW - glioma KW - temozolomide KW - radiotherapy KW - immunotherapy KW - novel therapy KW - personalized treatment KW - drug repurposing KW - invasion KW - invadopodia KW - ion channels KW - gene therapy KW - viral vectors KW - brain tumor KW - nanomedicine KW - cancer stem cell KW - targeted therapy KW - brain cancer KW - cell cycle KW - differentiation KW - proliferation KW - RAS KW - SRGAP2 KW - stem cell KW - TP53 KW - glioblastoma multiforme KW - GBM KW - nerve/glial antigen 2 KW - NG2 KW - CK2 KW - CX-4945 KW - migration KW - CRISPR/Cas9 KW - anticancer KW - anti-angiogenesis KW - thyrointegrin αvβ3 KW - PEG KW - triazole tetrac KW - P-bi-TAT KW - P-m-TAT KW - tetrac KW - one-carbon metabolism KW - de novo purine synthesis KW - metabolic reprogramming KW - metabolic treatment KW - vaccine KW - immune checkpoint inhibitors KW - chimeric antigen receptor (CAR) T cells KW - glioblastoma (GB) KW - prolyl-oligopeptidase (POP) KW - vascular endothelial growth factor (VEGF) KW - transforming growth factor-β (TGF-β) KW - angiopoietin (Ang) KW - endothelial nitric oxide synthase (eNOS) KW - newly diagnosed glioblastoma KW - recurrent glioblastoma KW - new trial design KW - drug-inducible gene expression KW - Mardepodect KW - Regorafenib KW - drug targets KW - tumor antigens KW - renin-angiotensin system KW - pluripotent stem cells KW - organoids KW - cancer stem cells KW - cancer stem cell niche KW - tumor microenvironment KW - glioblastoma KW - glioma KW - temozolomide KW - radiotherapy KW - immunotherapy KW - novel therapy KW - personalized treatment KW - drug repurposing KW - invasion KW - invadopodia KW - ion channels KW - gene therapy KW - viral vectors KW - brain tumor KW - nanomedicine KW - cancer stem cell KW - targeted therapy KW - brain cancer KW - cell cycle KW - differentiation KW - proliferation KW - RAS KW - SRGAP2 KW - stem cell KW - TP53 KW - glioblastoma multiforme KW - GBM KW - nerve/glial antigen 2 KW - NG2 KW - CK2 KW - CX-4945 KW - migration KW - CRISPR/Cas9 KW - anticancer KW - anti-angiogenesis KW - thyrointegrin αvβ3 KW - PEG KW - triazole tetrac KW - P-bi-TAT KW - P-m-TAT KW - tetrac KW - one-carbon metabolism KW - de novo purine synthesis KW - metabolic reprogramming KW - metabolic treatment KW - vaccine KW - immune checkpoint inhibitors KW - chimeric antigen receptor (CAR) T cells KW - glioblastoma (GB) KW - prolyl-oligopeptidase (POP) KW - vascular endothelial growth factor (VEGF) KW - transforming growth factor-β (TGF-β) KW - angiopoietin (Ang) KW - endothelial nitric oxide synthase (eNOS) KW - newly diagnosed glioblastoma KW - recurrent glioblastoma KW - new trial design KW - drug-inducible gene expression KW - Mardepodect KW - Regorafenib KW - drug targets KW - tumor antigens KW - renin-angiotensin system KW - pluripotent stem cells KW - organoids KW - cancer stem cells KW - cancer stem cell niche KW - tumor microenvironment UR - https://www.unicat.be/uniCat?func=search&query=sysid:145198909 AB - This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease. ER -